News and Trends 5 Dec 2022 Fallouh Healthcare’s device to give early diagnosis for post-surgery strangulation risk U.K.-based Fallouh Healthcare is developing a device to monitor cardiac patients after surgery, which is when a condition, called cardiac tamponade, can strike. The company says patients recovering from heart surgery can be at risk from the life-threatening condition that sees fluid build-up around the heart, strangling its ability to beat properly. Fallouh Healthcare, formed […] December 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 New company Liminatus Pharma Inc to develop three cancer treatments Clinical-stage biopharma company Liminatus Pharma LLC and Iris Acquisition Corp, a publicly traded special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed Liminatus Pharma, Inc.. The […] December 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Bactobio raises £6M to search for new antimicrobials U.K. biotech company Bactobio Ltd. has closed an oversubscribed £6 million ($7.4 million) bridge financing round. The financing was led by Bridford Group, with support from angel investors Peder Holk Nielsen (former CEO and president of Novozymes) and Hugh Grant (former chairman and CEO of Monsanto). New investors included the founders of the London-based fintech […] December 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […] November 30, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2022 Touchlight receives new grant to further develop doggybone DNA vaccine platform UK-based biotechnology company, Touchlight, has received a new grant from the Bill & Melinda Gates Foundation. The company will use the money to further its pre-clinical development of its doggybone DNA vaccine platform. The program aims to build on evidence that Touchlight’s rapid enzymatic doggybone DNA vaccines can produce strong neutralizing antibodies and durable T […] November 29, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2022 BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry BioPharma Dynamics have expanded their portfolio for the cell and gene therapy market to offer a range of chemically defined T-Cell media, DMSO-free cryopreservation solutions, and recombinant growth factors. Suitable for cell therapy applications at any stage, the portfolio of cell media products include immune cell media, stem cell media, and cell cryopreservation solutions. Supporting applications which […] November 29, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Deep Science Ventures and AbbVie to create companies to target inflammatory diseases Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the partners said they aim to unlock new approaches that not only make disease treatment better, but also present potential cures for patients. Immune-mediated inflammatory diseases […] November 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Replay receives $1.5M grant for hypoimmunogenic technology platform Genome writing company Replay has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell, a proprietary hypoimmunogenic technology platform. Replay’s uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (induced pluripotent stem cells) to be made immune silent. […] November 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Aptamer opens new facilities to meet growing demand for Optimer technology Aptamer Group developer of Optimer binders that enable development in the life sciences industry has opened new facilities in the UK’s York Science Park. It says this will enable it to meet the growing demand for Optimer technology. Well-known and respected neuroscience researcher, Baroness Susan Greenfield, opened the new 18,000 square-foot site on November 25. […] November 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2022 New function of CRISPR gene scissors discovered For several years, the CRISPR/Cas9 gene scissors have been causing a sensation in science and medicine. Researchers from the Institute of Structural Biology at the University Hospital Bonn (UKB) in Germany and the Medical Faculty of the University of Bonn, in cooperation with the partner University of St Andrews in Scotland and the European Molecular […] November 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Khondrion’s mitochondrial diseases treatment producing positive results Clinical-stage pharmaceutical company, Khondrion, discovering and developing therapies targeting primary mitochondrial diseases announced yesterday (November 22) its wholly-owned lead asset sonlicromanol for MELAS spectrum disorder has demonstrated positive treatment results. MELAS spectrum disorder is a rare progressive mitochondrial disease and sonlicromanol will move into a phase 3 registrational study supported by favorable benefit-risk profile. The […] November 23, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Trial to start for new heart attack drug A potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the U.K.: the Queen Elizabeth Hospital, Birmingham […] November 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email